Abstract
Stem cell transplantation is quickly developing as an attractive therapeutic option for regenerating tissues injured by cardiovascular disease. From embryonic to induced pluripotent stem cells, from injection of stem cells to differentiation of cardiac cell lineages, researchers continue to push the boundaries of how stem cells can be used in treatments. The major hurdle in the way of creating effective methods for tissue regeneration is immune rejection of transplanted materials; even undifferentiated stem cells can be recognized by the transplant recipients’ immune system, limiting their survival and overall beneficial potential. Posttransplant rejection of cellular materials does not always follow the same immunological progression, and as such, different types of stem cells can be rejected through distinct immune pathways. Therefore, a strong understanding of the known mechanisms behind stem cell immunogenicity—including specific cases of embryonic and patient-specific stem cell rejection—is pivotal for researchers to develop more efficient therapeutics. The future of stem cell transplantation research lies in developing techniques that prevent immune recognition of transplanted cells or tissues and in generating ready-to-use stem cell lines that can be quickly and easily prepared for transplantation.
This is a preview of subscription content, log in via an institution.
Abbreviations
- ES:
-
Embryonic stem
- HLA:
-
Human leukocyte antigen
- IFN:
-
Interferon
- iPS:
-
Induced pluripotent
- MHC:
-
Major histocompatibility complex
- miHA:
-
Minor histocompatibility antigen
- NK:
-
Natural killer
- NT-ESC:
-
Nuclear transfer embryonic stem cell
- TCR:
-
T cell receptor
- SCNT:
-
Somatic cell nuclear transfer
- SNPs:
-
Single nucleotide polymorphisms
References
de Almeida PE et al (2014) Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun 5:3903
Ardehali R et al (2013) Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue. Proc Natl Acad Sci U S A 110(9):3405–3410
Blum B, Benvenisty N (2008) The Tumorigenicity of human embryonic stem cells. Adv Cancer Res 100(08):133–158
Carpenter L et al (2012) Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev 21(6):977–986
Chiou S-H et al (2010) Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70(24):10433–10444
Deuse T et al (2011) Human leukocyte antigen I knockdown human embryonic stem cells induce host ignorance and achieve prolonged xenogeneic survival. Circulation 124(11 Suppl):S3–S9
Deuse T et al (2015) SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell 16(1):33–38
Drukker M et al (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 99(15):9864–9869
Dzierzak-Mietla M et al (2012) Occurrence and impact of minor histocompatibility antigens’ disparities on outcomes of hematopoietic stem cell transplantation from HLA-matched sibling donors. Bone Marrow Res 2012:257086
Goulmy E et al (1976) Alloimmunity to human H-Y. Lancet 2(7996):1206
Guleria I, Sayegh MH (2007) Maternal acceptance of the fetus: true human tolerance. J Immunol 178(6):3345–3351
He J-Q et al (2003) Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 93(1):32–39
Horton R et al (2004) Gene map of the extended human MHC. Nat Rev Genet 5(12):889–899
Hsu DC et al (2008) Long-term management of patients taking immunosuppressive drugs. Aust Prescr 32(3):68–71
Kambayashi T et al (2001) Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro. Eur J Immunol 31(3):869–875
Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358(6381):66–70
Khurana A, Brennan DC (2011) Pathology of solid organ transplantation. Springer-Verlag, Berlin, pp 11–31
Laflamme MA et al (2007) Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25(9):1015–1024
Li L et al (2004) Human embryonic stem cells possess immune-privileged properties. Stem Cells 22(4):448–456
Ma M et al (2011) Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. Stem Cells 28(9):1465–1475
Macedo C et al (2009) Contribution of naïve and memory t-cell populations to the human alloimmune response. Am J Transpl 9(9):2057–2066
Makkar R et al (2014) Abstract 20536: allogeneic heart stem cells to achieve myocardial regeneration (ALLSTAR): the one year phase I results. Circulation 130(Suppl 2):A20536–A20536
Makkar RR et al (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379(9819):895–904
Messina E (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95(9):911–921
Mummery C et al (2002) Cardiomyocyte differentiation of mouse and human embryonic stem cells*. J Anat 200(3):233–242
Neefjes J et al (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11(12):823–836
Nelson TJ et al (2009) Repair of acute myocardial infarction with iPS induced by human stemness factors. Circulation 120(5):408
Nussbaum J et al (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21(7):1345–1357
Schwartz SD et al (2012) Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379(9817):713–720
Schwartz SD et al (2015) Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385(9967):509–516
Spierings E (2014) Minor histocompatibility antigens: past, present, and future. Tissue Antigens 84(4):374–360
Starr TK, Jameson SC, Hogquist KA (2003) Positive and negativeselection of T cells. Ann Rev Immunol 21(1):139–176
Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3(11):879–889
Swijnenburg R-J, Schrepfer S, Govaert JA et al (2008a) Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A 105(35):12991–12996
Swijnenburg R-J, Schrepfer S, Cao F et al (2008b) In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev 17:1023–1029
Tachibana M et al (2013) Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153(6):1228–1238
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676
Taylor CJ et al (2012) Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient hla types. Cell Stem Cell 11(2):147–152
Templin C et al (2012) Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iod. Circulation 126(4):430–439
Thomson JA et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147
Vogt MH et al (2000) DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 95(3):1100–1105
Xu C et al (2002) Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 91(6):501–508
Yang Y et al (2002) VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells. J Appl Physiol 93(3):1140–1151
Zerrahn J, Held W, Raulet DH (1997) The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88(5):627–636
Zhao T et al (2015) Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 17(3):1–7
Zhao T et al (2011) Immunogenicity of induced pluripotent stem cells. Nature 474(7350):212–215
Zwi-Dantsis L et al (2013) Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients. Eur Heart J 34(21):1575–1586
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Miller, K.K., Schrepfer, S. (2017). Stem Cell Transplant Immunology. In: Ieda, M., Zimmermann, WH. (eds) Cardiac Regeneration. Cardiac and Vascular Biology, vol 4. Springer, Cham. https://doi.org/10.1007/978-3-319-56106-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-56106-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56104-2
Online ISBN: 978-3-319-56106-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)